Cleo Diagnostics (ASX:COV) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Cleo Diagnostics's Capital Expenditure for the six months ended in Dec. 2023 was A$-0.00 Mil. Its Operating Income for the six months ended in Dec. 2023 was A$-2.78 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Cleo Diagnostics Capex-to-Operating-Income Historical Data

The historical data trend for Cleo Diagnostics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Capex-to-Operating-Income Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Capex-to-Operating-Income

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Capex-to-Operating-Income	-	-	-

Competitive Comparison of Cleo Diagnostics's Capex-to-Operating-Income

For the Medical Devices subindustry, Cleo Diagnostics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics's Capex-to-Operating-Income Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Capex-to-Operating-Income falls into.

Cleo Diagnostics Capex-to-Operating-Income Calculation

Cleo Diagnostics's Capex-to-Operating-Income for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.34)	/	-1.729
	=	N/A

Cleo Diagnostics's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.002)	/	-2.782
	=	N/A

Cleo Diagnostics (ASX:COV) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Cleo Diagnostics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines